Eloxx Pharmaceuticals, Inc.
ELOX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001035354
No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $52.1M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +22 vs. previous quarter
- 22
- 13F valueReported value at the end of Q2 2026
- $34.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $0
- No comparable prior period
- Net income, FY2025
- -$6.00M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 52.6K
- Shares sold short
- Change
- +11.3K
- +27.2% vs. previous
- Days to cover
- 2.07
- At average daily volume
Superinvestors holding ELOX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ELOX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Eloxx Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 1, 2021 (view filing) | Nov 29 | 2 days | Geffken Daniel E.INTERIM CFO | PPurchase | +50.0K | $0.72 | +$36.0K | New position50.0K after |
Top 10 13F holders, Q2 2026
See all 22 holdersThe largest institutional positions in Eloxx Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 400,000 | $5.55M | 0.34% | +400,000 | New |
| EcoR1 Capital, LLC | 400,000 | $5.55M | 0.28% | +400,000 | New |
| Standard Life Aberdeen plc | 400,000 | $5.55M | 0.01% | +400,000 | New |
| Samsara BioCapital, LLC | 400,000 | $5.55M | 0.46% | +400,000 | New |
| Siren, L.L.C. | 400,000 | $5.55M | 0.11% | +400,000 | New |
| Stonepine Capital Management, LLC | 397,160 | $5.51M | 4.20% | +397,160 | New |
| Vanguard Capital Management LLC | 78,680 | $1.09M | 0.00% | +78,680 | New |
| Vanguard Fiduciary Trust Co | 10,602 | $147.2K | 0.00% | +10,602 | New |
| Seven Grand Managers, LLC | 10,000 | $138.8K | 0.01% | +10,000 | New |
| Morgan Stanley | 1,544 | $21.4K | 0.00% | +1,544 | New |
Holders of 5% or more of ELOX
See all 9 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Eloxx Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Domicilium Real Estate Fund III LP | 13G | 19.99%855.0K shares | +15.09 ppfrom 4.90% | Jun 5, 20262 filings | Jun 17, 2026 | SEC |
| Domicilium Real Estate Fund III LP | 13G | 18.60%1.41M shares | New | May 4, 20261 filing | May 4, 2026 | SEC |
| Coastlands Capital LP | 13G | 9.99%410.5K shares | +5.00 ppfrom 4.99% | May 1, 20263 filings | Jun 17, 2026 | SEC |
| Invus Global Management, LLC | 13G | 9.99%403.6K shares | New | Jun 15, 20261 filing | Jun 15, 2026 | SEC |
| Nantahala Capital Management, LLC | 13G | 9.91%400.0K shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |